Determinants of time to institutionalisation and related healthcare and societal costs in a community-based cohort of patients with Alzheimer's disease dementia.
Aged
Aged, 80 and over
Alzheimer Disease
/ economics
Caregivers
Cohort Studies
Comorbidity
Cost of Illness
Costs and Cost Analysis
Europe
Female
Health Care Costs
/ statistics & numerical data
Humans
Independent Living
/ economics
Institutionalization
/ economics
Likelihood Functions
Male
Prospective Studies
Severity of Illness Index
Alzheimer’s disease
Caregiver
Institutionalisation
Predictors
Societal costs
Journal
The European journal of health economics : HEPAC : health economics in prevention and care
ISSN: 1618-7601
Titre abrégé: Eur J Health Econ
Pays: Germany
ID NLM: 101134867
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
12
10
2017
accepted:
27
08
2018
pubmed:
5
9
2018
medline:
27
8
2019
entrez:
5
9
2018
Statut:
ppublish
Résumé
To examine the costs of caring for community-dwelling patients with Alzheimer's disease (AD) dementia in relation to the time to institutionalisation. GERAS was a prospective, non-interventional cohort study in community-dwelling patients with AD dementia and their caregivers in three European countries. Using identified factors associated with time to institutionalisation, models were developed to estimate the time to institutionalisation for all patients. Estimates of monthly total societal costs, patient healthcare costs and total patient costs (healthcare and social care together) prior to institutionalisation were developed as a function of the time to institutionalisation. Of the 1495 patients assessed at baseline, 307 (20.5%) were institutionalised over 36 months. Disease severity at baseline [based on Mini-Mental State Examination (MMSE) scores] was associated with risk of being institutionalised during follow up (p < 0.001). Having a non-spousal informal caregiver was associated with a faster time to institutionalisation (944 fewer days versus having a spousal caregiver), as was each one-point worsening in baseline score of MMSE, instrumental activities of daily living and behavioural disturbance (67, 50 and 30 fewer days, respectively). Total societal costs, total patient costs and, to a lesser extent, patient healthcare-only costs were associated with time to institutionalisation. In the 5 years pre-institutionalisation, monthly total societal costs increased by more than £1000 (€1166 equivalent for 2010) from £1900 to £3160 and monthly total patient costs almost doubled from £770 to £1529. Total societal costs and total patient costs rise steeply as community-dwelling patients with AD dementia approach institutionalisation.
Identifiants
pubmed: 30178148
doi: 10.1007/s10198-018-1001-3
pii: 10.1007/s10198-018-1001-3
pmc: PMC6438944
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Pagination
343-355Subventions
Organisme : Eli Lilly and Company
ID : N/A
Références
J Gerontol A Biol Sci Med Sci. 2001 Nov;56(11):M693-9
pubmed: 11682577
JAMA. 2002 Apr 24;287(16):2090-7
pubmed: 11966383
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1315-6
pubmed: 12933944
Lancet. 2004 Jun 26;363(9427):2105-15
pubmed: 15220031
Psychol Med. 2004 Aug;34(6):1129-35
pubmed: 15554582
J Int Neuropsychol Soc. 2005 Jul;11(4):446-53
pubmed: 16209425
Age Ageing. 2006 May;35(3):308-10
pubmed: 16533876
J Gerontol B Psychol Sci Soc Sci. 2006 Jul;61(4):P220-7
pubmed: 16855034
Gerontologist. 2007 Dec;47(6):730-40
pubmed: 18192627
J Am Geriatr Soc. 2008 Jun;56(6):1116-28
pubmed: 18410323
Dement Geriatr Cogn Disord. 2008;26(1):65-78
pubmed: 18617737
Med Care. 2009 Feb;47(2):191-8
pubmed: 19169120
J Neurol Neurosurg Psychiatry. 2009 Jun;80(6):600-7
pubmed: 19204022
Int J Geriatr Psychiatry. 2009 Nov;24(11):1291-8
pubmed: 19340893
J Med Econ. 2009 Jun;12(2):98-103
pubmed: 19492974
Acta Psychiatr Scand. 2010 Apr;121(4):243-59
pubmed: 19694634
J Med Econ. 2010;13(2):362-70
pubmed: 20504113
Gerontologist. 2011 Feb;51(1):17-27
pubmed: 20562471
Alzheimers Dement. 2011 May;7(3):318-27
pubmed: 21575872
Alzheimers Dement. 2011 Jul;7(4):466-73
pubmed: 21784355
Value Health. 2011 Jul-Aug;14(5):621-30
pubmed: 21839398
Can J Psychiatry. 2011 Oct;56(10):596-604
pubmed: 22014692
Health Technol Assess. 2012;16(21):1-470
pubmed: 22541366
Alzheimers Dement. 2013 Jan;9(1):1-11.e3
pubmed: 23305821
Med Decis Making. 2013 Aug;33(6):743-54
pubmed: 23341049
Neurodegener Dis Manag. 2012 Oct 1;2(5):483-491
pubmed: 23585777
J Alzheimers Dis. 2013;36(2):385-99
pubmed: 23629588
PLoS One. 2013 Jul 18;8(7):e70018
pubmed: 23875017
Eur J Health Econ. 2014 Nov;15(8):791-800
pubmed: 23928827
J Am Med Dir Assoc. 2014 Feb;15(2):108-16
pubmed: 24238605
J Am Med Dir Assoc. 2014 Feb;15(2):117-26
pubmed: 24321877
Dement Geriatr Cogn Dis Extra. 2013 Nov 01;3(1):426-45
pubmed: 24348504
J Alzheimers Dis. 2014;40(1):221-6
pubmed: 24448780
Dement Geriatr Cogn Dis Extra. 2014 Feb 19;4(1):51-64
pubmed: 24711814
Eur J Health Econ. 2015 Sep;16(7):689-707
pubmed: 25069577
Int J Geriatr Psychiatry. 2015 Feb;30(2):111-29
pubmed: 25320002
Dement Geriatr Cogn Dis Extra. 2014 Jun 28;4(2):195-208
pubmed: 25337076
Alzheimers Dement. 2015 Aug;11(8):933-45
pubmed: 25846298
Int Psychogeriatr. 2016 Feb;28(2):247-59
pubmed: 26307191
Lancet Neurol. 2015 Dec;14(12):1171-81
pubmed: 26515660
J Alzheimers Dis. 2017;57(3):797-812
pubmed: 28304285
Neurology. 1984 Jul;34(7):939-44
pubmed: 6610841
Neurology. 1997 May;48(5 Suppl 6):S10-6
pubmed: 9153155
Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S33-9
pubmed: 9236950
Age Ageing. 1997 Sep;26 Suppl 2:3-12
pubmed: 9464548